Shots:

• GSK to invest in Vir with $250M at $37.73- a 10% premium to the closing share price on Friday- March 27- 2020 and enters into an agreement to develop a potential Ab treatment against COVID-19
• The alliance will leverage Vir’s mAb platform to identify Ab that can be used as preventive option addressing COVID-1 and utilize GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and AI to identify anti-coronavirus compounds targeting the cellular host genes
• Initially- the companies will accelerate Vir’s Ab- VIR-7831 and VIR-7832 that demonstrates high affinity in neutralizing SARS-CoV-2 and is expected to be accelerated into P-II studies within the next 3-5mos.

Click here ­to­ read full press release/ article 

Ref: GSK | Image: GSK